The UK sleep-wake disorder market is estimated to grow at a CAGR of 6.2% during the forecast period. UK contributes a considerable share in the market due to the presence of a significant number of people with behavioral health disorders and the growing awareness of sleep disorders in the country. Mental Health First Aid (MHFA) England is a social organization that offers expert guidance and training to support mental health. According to the MHFA statistics 2019, 1 in 4 people faces mental health issues each year and responsible for 72 million working days lost and costs $45.5 billion each year. Additionally, 1 in 6 workers experience depression, anxiety or problems relating to stress at any one time and 526,000 cases of work-related stress, depression or anxiety were recorded in 2016-2017 in Great Britain as per MHFA.  In 2016-2017, stress was responsible for 40% of all cases of work-related ill health and for 49% of all working days lost due to health issues in the country as per MHFA. Therefore, work-related stress raises the risk of sleep disorders that further increases the demand for effective treatment.  

The market is segmented on the basis of type and treatment. Based on type, the market is sub-segmented into insomnia, hypersomnia, sleep apnea, circadian rhythm disorders, and others. Sleep apnea holds the largest market share during the forecast period. On the basis of treatment, the market is divide into therapies, drugs, and devices. The sleep-wake disorder devices segment is estimated to hold the largest market share during the forecast period, followed by medications. Some of the players operating in the market include Koninklijke Philips N.V, Medtronic PLC, Sanofi SA, Jazz Pharmaceutical Inc., and others.

In January 2020, Jazz Pharmaceuticals, SK Biopharmaceutical’s US partner received sales approval from the European Medicine Agency (EMA) for Sunosi (Ingredient: solriamfetol), a treatment for improving wakefulness in patients suffering from excessive daytime sleepiness related with narcolepsy or obstructive sleep apnea. SK Biopharmaceutical discovered Sunosi and completed its phase 1 clinical trial before licensing out the substance to Aerial BioPharma in 2011. Thereafter, Jazz Pharmaceuticals took over the global commercialization rights, including the US and Europe, for completing the phase 3 clinical trials for the drug. With this approval, Jazz Pharma has planned to launch Sunosi in Germany in mid-2020 and then to France and UK by early 2021.

Research Methodology

The market study of the UK sleep-wake disorder market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for hospitals, sleep disorder device manufacturers, drug manufacturers, physicians, senior care centers, nursing centers, research organizations, investment companies, government organizations, regulatory authorities, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. 

Market Segmentation

1. UK Sleep-Wake Disorder Market Research and Analysis by Type
2. UK Sleep-Wake Disorder Market Research and Analysis by Treatment

The Report Covers

• Comprehensive research methodology of the UK Sleep-Wake Disorder Market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK Sleep-Wake Disorder Market.
• Insights about market determinants which are stimulating the UK Sleep-Wake Disorder Market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.